CN
CN

CN
Antiviral Services

In Vitro Research Platforms

 

  • Antiviral services: Cell-based and biochemical assays for HBV, RSV, influenza, HPIV, HIV, HSV, HCMV, ZIKA, HRV, EV71, CV and HCV for compound screening and profiling, resistance characterization, HTS and MOA studies
  • Support to clinical trials: Genotyping, VL determination, sequencing and phenotyping for HCV and HBV clinical trials; genotyping for RSV clinical trials

 

 

In Vivo Models

 

  • HDI, AAV/HBV and humanized mouse models for HBV, mouse and cotton rat pulmonary infection models for RSV, mouse lethal model for influenza virus, mouse lethal model for HSV and EV71, mouse xenograft model for HCMV

 

 

Hepatitis B Virus (HBV)

 

  • Compound screening
    • 2.15, DE19 and DES19 cell lines with qPCR, RT-qPCR, Southern blot, Northern blot, Western blot, ELISA and IF
    • Reporter cell lines (hTLR reporter, THP1-Blue™ ISG, TNF-Induced NF-κB-luciferase cell, etc.)
    • Biochemistry: capsid assembly quenching assay
  • Compound profiling: nuc and CpAM-resistance constructs, genotypes (A to J) and clinical strains, drug combination, serum shift, etc.
  • Ex vivo primary human hepatocytes (PHH) infectious system
  • In vivo models: HDI, AAV/HBV and humanized liver mouse models, endpoints with viral DNA, RNA and proteins in plasma and liver, and liver enzymes
  • HBV related immunological assays: cytokines, IFN/ISG and other immune markers (ELISA, Luminex, RT-qPCR, IF, IHC and Western blot), immune cell analysis (FACS, ICS and ELISPOT)
  • Support of clinical trials: VL, genotyping, sequencing, phenotyping, cytokines, pgRNA, HBcrAg
  • MOA studies: CpAM and customer tailored MOA studies

 

 

Respiratory Syncytial Virus (RSV)

 

  • Compound screening: RSV A and B lab and clinical strains with CPE, ELISA, neutralization and plaque reduction assays
  • Compound profiling: drug resistance, genotypic spectrum and drug combination
  • In vivo model: mouse or cotton rat pulmonary infection models with VL plaque assay
  • Support of clinical trials: VL, genotyping
  • MOA: F protein-mediated cell fusion

 

 

Influenza Virus (IFV)

 

  • Compound screening/profiling
    • A mini panel of IFV A H1N1 and H3N2, and IFV B strains with CPE, plaque and RT-qPCR
    • Highly pathogenic avian influenza H5N1 and H7N9 strains
    • Drug resistance, drug combination
  • In vivo model: mouse pulmonary infection with mortality and VL titration
  • Biochemistry: neuraminidase, hemagglutinin
  • Viral protein and replication complex purification from infected hen eggs

 

 

Human Parainfluenza Virus (HPIV)

 

  • HPIV-3 CPE assay

 

 

Human Immunodeficiency Virus (HIV)

 

  • HIV CPE assay in a subcontract lab
  • Viral enzymes

 

 

Herpes Simplex Virus (HSV)

 

  • Compound screening/profiling: HSV-1 and HSV-2, CPE and reporter assays
  • In vivo model: mouse lethal and ocular latent infection/activation models
  • Ex vivo model: isolation and cultivation of latently infected ganglia neurons

 

 

Human Cytomegalovirus (HCMV)

 

  • Compound screening: CPE and reporter assays
  • In vivo model: mouse xenograft model with VL titration

 

 

Zika Virus

 

  • Compound screening: CPE and plaque reduction assay
  • In vivo model: mouse lethal model with VL RT-qPCR

 

 

Picornaviruses

 

  • Human rhinovirus (HRV): mini panel of HRV strains, CPE assay
  • Enterovirus 71 (EV71, hand-foot-mouth disease): CPE, mouse lethal and VL RT-qPCR model
  • Coxsackie virus (CV): A16 and B3, CPE assay

 

 

Hepatitis C Virus (HCV)

 

  • Compound screening: stable and transient replicons, and HCVcc with luciferase reporter and RT-qPCR
  • Compound profiling: drug resistance, genotypic spectrum, drug combination and serum shift
  • Support to clinical trials: VL, genotyping and phenotyping
  • Biochemistry: viral enzymes

 

 

Learn More 

 

 

Business Contact：